United States - English - NLM (National Library of Medicine)

teva respiratory, llc - beclomethasone dipropionate (unii: 5b307s63b2) (beclomethasone - unii:kgz1slc28z) - beclomethasone dipropionate 80 ug - qnasl® nasal aerosol is indicated for the treatment of the nasal symptoms associated with seasonal and perennial allergic rhinitis in patients 4 years of age and older. qnasl nasal aerosol is contraindicated in patients with a history of hypersensitivity to beclomethasone dipropionate and/or any other qnasl nasal aerosol ingredients [see warnings and precautions (5.3)] . teratogenic effects : pregnancy category c there are no adequate and well-controlled clinical trials in pregnant women treated with qnasl nasal aerosol. beclomethasone dipropionate was teratogenic and embryocidal in the mouse and rabbit although these effects were not observed in rats. qnasl nasal aerosol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. experience with oral corticosteroids since their introduction in pharmacologic, as opposed to physiologic, doses suggests that rodents are more prone to teratogenic effects from corticosteroids than humans. beclomethasone dipropionate ad

Malta - English - Medicines Authority

generics uk limited station close, potters bar, herts, en6 1tl, united kingdom - beclometasone dipropionate - nasal spray, solution - beclometasone dipropionate 50 µg - nasal preparations

United States - English - NLM (National Library of Medicine)

teva respiratory, llc - beclomethasone dipropionate (unii: 5b307s63b2) (beclomethasone - unii:kgz1slc28z) - beclomethasone dipropionate 40 ug - qvar® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. important limitations of use: - qvar is not indicated for the relief of acute bronchospasm. 4.1 status asthmaticus qvar is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. 4.2 hypersensitivity qvar is contraindicated in patients with known hypersensitivity to beclomethasone dipropionate or any of the ingredients in qvar [see warnings and precautions (5.6)]. risk summary there are no adequate and well-controlled studies with qvar or beclomethasone dipropionate in pregnant women. there are clinical considerations with the use of inhaled corticosteroids (ics), including beclomethasone dipropionate, in pregnant women [see clinical considerations] . also, no published studies, including studies of large birth registries, have to date related the use of ics to any increases in congenital malformations or other

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - beclomethasone dipropionate (unii: 5b307s63b2) (beclomethasone - unii:kgz1slc28z) - beclomethasone dipropionate 80 ug - qvar® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. important limitations of use: 4.1 status asthmaticus qvar is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. 4.2 hypersensitivity qvar is contraindicated in patients with known hypersensitivity to beclomethasone dipropionate or any of the ingredients in qvar [see warnings and precautions (5.6)]. risk summary there are no adequate and well-controlled studies with qvar or beclomethasone dipropionate in pregnant women. there are clinical considerations with the use of inhaled corticosteroids (ics), including beclomethasone dipropionate, in pregnant women [see clinical considerations] . also, no published studies, including studies of large birth registries, have to date related the use of ics to any increases in congenital malformations or other adverse perinatal outcomes. thus, available human data do not

United States - English - NLM (National Library of Medicine)

stat rx usa llc - beclomethasone dipropionate (unii: 5b307s63b2) (beclomethasone 17-monopropionate - unii:5bga9fd55h) - beclomethasone 17-monopropionate 40 ug - qvar is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. qvar is also indicated for asthma patients who require systemic corticosteroid administration, where adding qvar may reduce or eliminate the need for the systemic corticosteroids. beclomethasone dipropionate is not indicated for the relief of acute bronchospasm. qvar is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. hypersensitivity to any of the ingredients of this preparation contraindicates its use.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - beclomethasone dipropionate (unii: 5b307s63b2) (beclomethasone 17-monopropionate - unii:5bga9fd55h) - beclomethasone dipropionate 40 ug - qvar is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. qvar is also indicated for asthma patients who require systemic corticosteroid administration, where adding qvar may reduce or eliminate the need for the systemic corticosteroids. beclomethasone dipropionate is not indicated for the relief of acute bronchospasm. qvar is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. hypersensitivity to any of the ingredients of this preparation contraindicates its use.

United States - English - NLM (National Library of Medicine)

teva respiratory, llc - beclomethasone dipropionate (unii: 5b307s63b2) (beclomethasone - unii:kgz1slc28z) - qnasl® nasal aerosol is indicated for the treatment of the nasal symptoms associated with seasonal and perennial allergic rhinitis in patients 4 years of age and older. qnasl nasal aerosol is contraindicated in patients with a history of hypersensitivity to beclomethasone dipropionate and/or any other qnasl nasal aerosol ingredients [see warnings and precautions (5.3)] .  risk summary there are no adequate and well-controlled studies with qnasl nasal aerosol or beclomethasone dipropionate in pregnant women. no published studies, including studies of large birth registries, have to date related the use of inhaled corticosteroids (ics) or intranasal corticosteroids to any increases in congenital malformations or other adverse perinatal outcomes.  thus, available human data do not establish the presence or absence of drug‑associated risk to the fetus.  in animal reproduction studies, beclomethasone dipropionate resulted in adverse developmental effects in mice and rabbits at subcutaneous doses equal to or great

Canada - English - Health Canada

apotex inc - beclomethasone dipropionate - suspension - 50mcg - beclomethasone dipropionate 50mcg - corticosteroids

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - beclomethasone dipropionate (unii: 5b307s63b2) (beclomethasone - unii:kgz1slc28z) - beclomethasone dipropionate 40 ug

United States - English - NLM (National Library of Medicine)

stat rx usa llc - beclomethasone dipropionate monohydrate (unii: 4h7l9ai22i) (beclomethasone - unii:kgz1slc28z) - beclomethasone dipropionate monohydrate 42 ug - beconase aq nasal spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis. results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days. however, symptomatic relief may not occur in some patients for as long as 2 weeks. beconase aq nasal spray should not be continued beyond 3 weeks in the absence of significant symptomatic improvement. beconase aq nasal spray should not be used in the presence of untreated localized infection involving the nasal mucosa. beconase aq nasal spray is also indicated for the prevention of recurrence of nasal polyps following surgical removal. clinical studies have shown that treatment of the symptoms associated with nasal polyps may have to be continued for several weeks or more before a therapeutic result can be fully assessed. recurrence of symptoms due to polyps can occur after stopping treatment, depending on the severity of the disease. hypersensitivity to an